On The Pen GLP-1 News

On The Pen GLP-1 News

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.


Den här podcasten är hämtad från ett öppet RSS-flöde och publiceras inte av Podme. Den kan innehålla reklam.

Avsnitt(197)

How To Get $50 GLP-1

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Juni 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ​⁠ to break down the molecules, clinica...

16 Juni 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Juni 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Juni 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Juni 20min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

26 Maj 30min

Lilly Bets $8B on Weight Loss Future

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

19 Maj 23min

The Next Two Weeks in GLP1 Are Huge, Here's Why

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

12 Maj 1h 7min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
inga-beiga-morsor
rss-vuxna-pa-latsas
sexnoveller-deluxe
not-fanny-anymore
rss-viktmedicinpodden
sova-med-dan-horning
angestpodden
johannes-hansen-podcast
sa-in-i-sjalen
medicinvetarna
tyngre-radio
rss-vad-hander-bror
rss-autismandan
smartare-fitness-podden
rss-sjalsligt-avkladd
dodsdomar
rss-basta-livet
rss-pappahjartat